business

AbbVie Pursues Nearly $11 Billion Acquisition of Apogee Therapeutics

19 Haziran 2026Financial Times

AbbVie is nearing a significant acquisition of Apogee Therapeutics for nearly $11 billion. This move is part of a broader trend in the biotech sector, where major pharmaceutical companies are actively seeking to enhance their drug pipelines through strategic buyouts.
The deal highlights the increasing competition and investment in biotech as companies aim to innovate and expand their product offerings.
The biotech industry has seen a resurgence in dealmaking activity, driven by the ongoing demand for novel therapies and the rapid pace of innovation. As companies like AbbVie look to diversify and strengthen their offerings, the landscape of pharmaceutical acquisitions is evolving, with smaller biotech firms becomin…
This acquisition underscores the aggressive strategies employed by Big Pharma to secure promising biotech firms. As the industry faces pressures from patent expirations and the need for new therapies, such mergers and acquisitions are likely to accelerate.

NewsAI özeti

This summary is based on information from the Financial Times and is intended for informational purposes only.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.